NSCLC
-
May 27, 2015
‘Immune Checkpoint’ Drugs Show New Promise for Treating Non-Small Cell Lung Cancer
Emma Shtivelman, PhDIt has become routine practice to prescribe targeted drugs to patients with metastatic non-small cell lung cancer (NSCLC), whose tumors harbor molecular alterations in EGFR, ALK, and ROS. However, the majority of patients with NSCLC have no targetable mutations and lack good treatment options. Enter immunotherapy drugs, specifically ‘immune checkpoint blockade antibodies,’ to which many refer simply as ‘anti-PD-1 drugs,’ or simply ‘PD-1 drugs.’… Read more »
-
February 10, 2015
New Drugs Aim to Defeat Tumor Resistance to EGFR Inhibitors
Emma Shtivelman, PhDIn recent years, many people with non-small cell lung cancer (NSCLC) have been successfully treated with drugs called EGFR inhibitors. But over time, most patients develop resistance to these drugs, and the drugs stop working. Researchers are hard at work developing new drugs to help patients who can no longer be treated with EGFR inhibitors.